Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 427

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 427
---
 payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction; |

| • |     | patent applications may not result in any patents being issued; |

| • |     | if clinical trials encounter delays, the period of time during which we could market our current or future 
 product candidates under patent protection would be reduced;                                               |

| • |     | patents may be challenged, invalidated, modified, narrowed, revoked, circumvented, found to be unenforceable, 
 found to be not infringed or otherwise may not provide any competitive advantage;                             |

| • |     | our competitors, many of whom have substantially greater resources than we do and many of whom have made 
 significant investments in competing technologies, may seek or may have already obtained                 |

- 287 -

| patents that could limit, interfere with or eliminate our ability to make, use and sell our product or potential product candidates or design around any of our owned, co-owned, or licensed patents; |

| • |     | since patent applications in the United States and most other countries are confidential for a period of time                                                                                                   
 after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product; or (ii) invent any of the inventions claimed in our patents or patent applications; |

| • |     | even when laws provide protection, costly and time-consuming litigation could be necessary to enforce and                                                                                                                                               
 determine the scope of our proprietary rights, and the outcome of such litigation would be uncertain. Moreover, any actions we may bring to enforce our intellectual property against our competitors could provoke them to bring counterclaims against 
 us;                                                                                                                                                                                                                                                     |

| • |     | there may be significant pressure on the United States government and international governmental bodies to limit                                                                             
 the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and |

| • |     | countries other than the United States may have patent laws less favorable to patentees than those upheld by                                    
 United States courts, allowing foreign competitors a better opportunity to create, develop and market competing products or product candidates. |

The patent prosecution process is also expensive, complex, and time-consuming, and we and our licensors may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a